drugset / Trial / NCT00707252
Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer
Phase 1
Terminated
11 enrolled
Louisiana State University Health Sciences Center Shreveport
Polyphenon E International,Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to study if the addition of the green tea extract, Polyphenon E, to Erlotinib is safe and if it has potential to improve outcomes in second line therapy for Advanced Stage IIIb/IV Non-small cell lung cancer.
Timeline
- Start
- 2008-01
- Primary completion
- 2012-11
- Completion
- 2012-11
Outcome
Outcome not reported
Stopped: “Phase II not initiated due to cancellation of supply of Poly E by collaborator.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sinecatechins | Unknown | 200 mg | — |
| Subject | Sinecatechins | Unknown | 400 mg | — |
| Subject | Sinecatechins | Unknown | 800 mg | — |
| Background | Erlotinib | Small molecule | 150 mg | Oral |